,0
zip,02142
sector,Healthcare
fullTimeEmployees,9610
longBusinessSummary,"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts."
city,Cambridge
phone,617 679 2000
state,MA
country,United States
companyOfficers,[]
website,https://www.biogen.com
maxAge,1
address1,225 Binney Street
industry,Drug Manufacturersâ€”General
ebitdaMargins,0.35727
profitMargins,0.1417
grossMargins,0.80789
operatingCashflow,3639899904
revenueGrowth,-0.042
operatingMargins,0.31285998
ebitda,3923399936
targetLowPrice,185
recommendationKey,buy
grossProfits,8872000000
freeCashflow,2206412544
targetMedianPrice,238
currentPrice,210.97
earningsGrowth,0.075
currentRatio,1.828
returnOnAssets,0.088549994
numberOfAnalystOpinions,29
targetMeanPrice,252.62
debtToEquity,70.19
returnOnEquity,0.15962
targetHighPrice,400
totalCash,3802500096
totalDebt,7692599808
totalRevenue,10981699584
totalCashPerShare,25.874
financialCurrency,USD
revenuePerShare,73.653
quickRatio,1.341
recommendationMean,2.5
exchange,NMS
shortName,Biogen Inc.
longName,Biogen Inc.
exchangeTimezoneName,America/New_York
exchangeTimezoneShortName,EDT
isEsgPopulated,False
gmtOffSetMilliseconds,-14400000
quoteType,EQUITY
symbol,BIIB
messageBoardId,finmb_29726
market,us_market
annualHoldingsTurnover,
enterpriseToRevenue,3.183
beta3Year,
enterpriseToEbitda,8.91
52WeekChange,-0.23583746
morningStarRiskRating,
forwardEps,16.47
revenueQuarterlyGrowth,
sharesOutstanding,146963008
fundInceptionDate,
annualReportExpenseRatio,
totalAssets,
bookValue,74.124
sharesShort,2198762
sharesPercentSharesOut,0.015
fundFamily,
lastFiscalYearEnd,1640908800
heldPercentInstitutions,0.86557
netIncomeToCommon,1556099968
trailingEps,10.4
lastDividendValue,
SandP52WeekChange,0.14403355
priceToBook,2.8461766
heldPercentInsiders,0.00677
nextFiscalYearEnd,1703980800
yield,
mostRecentQuarter,1640908800
shortRatio,1.96
sharesShortPreviousMonthDate,1644883200
floatShares,146541010
beta,0.447342
enterpriseValue,34958340096
priceHint,2
threeYearAverageReturn,
lastSplitDate,979776000
lastSplitFactor,3:1
legalType,
lastDividendDate,
morningStarOverallRating,
earningsQuarterlyGrowth,0.029
priceToSalesTrailing12Months,2.823314
dateShortInterest,1647302400
pegRatio,-1.49
ytdReturn,
forwardPE,12.809351
lastCapGain,
shortPercentOfFloat,0.016900001
sharesShortPriorMonth,2542355
impliedSharesOutstanding,0
category,
fiveYearAverageReturn,
previousClose,213.01
regularMarketOpen,213.32
twoHundredDayAverage,276.42514
trailingAnnualDividendYield,0
payoutRatio,0
volume24Hr,
regularMarketDayHigh,214.03
navPrice,
averageDailyVolume10Day,1152840
regularMarketPreviousClose,213.01
fiftyDayAverage,214.7418
trailingAnnualDividendRate,0
open,213.32
toCurrency,
averageVolume10days,1152840
expireDate,
algorithm,
dividendRate,
exDividendDate,
circulatingSupply,
startDate,
regularMarketDayLow,209.41
currency,USD
trailingPE,20.285578
regularMarketVolume,564822
lastMarket,
maxSupply,
openInterest,
marketCap,31004786688
volumeAllCurrencies,
strikePrice,
averageVolume,1549801
dayLow,209.41
ask,210.15
askSize,800
volume,564822
fiftyTwoWeekHigh,468.55
fromCurrency,
fiveYearAvgDividendYield,
fiftyTwoWeekLow,192.67
bid,210.48
tradeable,False
dividendYield,
bidSize,800
dayHigh,214.03
regularMarketPrice,210.97
preMarketPrice,
logo_url,https://logo.clearbit.com/biogen.com
